Overall, 20 of the 25 firms in the index saw their share prices grow in May, including seven whose stocks rose more than 20 percent compared to April.
Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company claims its test can detect the Lyme-linked chemokine CXCL13 in human cerebrospinal fluid within 20 minutes.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.